Gene · 64005
Papers2,247
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,247
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus. | Front Immunol | 2024 | 38482020 | PubTator, text mining | PubMed |
| Targeted nonviral delivery of genome editors in vivo. | Proc Natl Acad Sci U S A | 2024 | 38437567 | PubTator, text mining | PubMed |
| Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications. | BME Front | 2024 | 38282957 | PubTator, text mining | PubMed |
| Combined Role of Interleukin-15 Stimulated Natural Killer Cell-Derived Extracellular Vesicles and Carboplatin in Osimertinib-Resistant H1975 Lung Cancer Cells with EGFR Mutations. | Pharmaceutics | 2024 | 38258094 | PubTator, text mining | PubMed |
| Sequential Immunizations with Influenza Neuraminidase Protein Followed by Peptide Nanoclusters Induce Heterologous Protection. | Viruses | 2024 | 38257777 | PubTator, text mining | PubMed |
| Herpesviruses and SARS-CoV-2: Viral Association with Oral Inflammatory Diseases. | Pathogens | 2024 | 38251365 | PubTator, text mining | PubMed |
| Rare Ophiuroid-Type Steroid 3β,21-, 3β,22-, and 3α,22-Disulfates from the Slime Sea Star Pteraster marsippus and Their Colony-Inhibiting Effects against Human Breast Cancer Cells. | Mar Drugs | 2024 | 38248668 | PubTator, text mining | PubMed |
| Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice. | Int J Biol Macromol | 2024 | 38191112 | PubTator, text mining | PubMed |
| Unveiling the role of host kinases at different steps of influenza A virus life cycle. | J Virol | 2024 | 38174932 | PubTator, text mining | PubMed |
| Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin. | Proc Natl Acad Sci U S A | 2024 | 38147556 | PubTator, text mining | PubMed |
| Engineered smart materials for RNA based molecular therapy to treat Glioblastoma. | Bioact Mater | 2024 | 38059120 | PubTator, text mining | PubMed |
| M6PR interacts with the HA2 subunit of influenza A virus to facilitate the fusion of viral and endosomal membranes. | Sci China Life Sci | 2024 | 38038885 | PubTator, text mining | PubMed |
| Self-Assembled Multiepitope Nanovaccine Provides Long-Lasting Cross-Protection against Influenza Virus. | Adv Healthc Mater | 2024 | 37983728 | PubTator, text mining | PubMed |
| The Hybrid of Cu─TCPP@Mn3 O4 for Inflammation Relief by ROS Scavenging and O2 Production: An Efficient Strategy for Antiviral Therapy. | Small | 2024 | 37903361 | PubTator, text mining | PubMed |
| Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing. | Front Immunol | 2023 | 38283342 | PubTator, text mining | PubMed |
| Has avian influenza virus H9 originated from a bat source? | Front Vet Sci | 2023 | 38260204 | PubTator, text mining | PubMed |
| Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand. | Pharmaceutics | 2023 | 38258035 | PubTator, text mining | PubMed |
| Design of protein-binding peptides with controlled binding affinity: the case of SARS-CoV-2 receptor binding domain and angiotensin-converting enzyme 2 derived peptides. | Front Mol Biosci | 2023 | 38250735 | PubTator, text mining | PubMed |
| Antigenic Architecture of the H7N2 Influenza Virus Hemagglutinin Belonging to the North American Lineage. | Int J Mol Sci | 2023 | 38203384 | PubTator, text mining | PubMed |
| Immunological Aspects of Infertility-The Role of KIR Receptors and HLA-C Antigen. | Cells | 2023 | 38201263 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64005/papers?page=3